<DOC>
	<DOCNO>NCT00277238</DOCNO>
	<brief_summary>The purpose study determine efficacy tolerability CPG 10101 two different dose level pegylated-interferon-alpha 2B ( PEG-IFN ) plus ribavirin ( RBV ) compare PEG-IFN RBV without CPG 10101 HCV positive subject classify non-responders previous adequate PEG-IFN plus RBV therapy .</brief_summary>
	<brief_title>CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder ( Null And Partial Responder ) Hepatitis C Virus ( HCV ) Genotype 1 Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>HCV positive subject document serum HCV RNA concentration &gt; 100,000 IU/mL within 21 day first study treatment Receipt adequate previous PEGIFN RBV therapy minimum 12 week ( PEGIFN alpha2a dose &gt; 180 μg/wk PEGIFN alpha2b 1.5 µg/kg/wk least 800 mg RBV daily ) result minimum 2 log decrease HCV RNA concentration treatment ( null responder ) . Or , receipt adequate previous treatment PEGIFN RBV therapy minimum 24 week ( PEGIFN alpha2a dose ≥ 180 μg/wk PEGIFN alpha2b 1.5 µg/kg/wk least 800 mg RBV daily ) result minimum 2 log decrease serum HCV RNA concentration 12 week treatment result undetectable viral load 24 week treatment ( partial responder ) . If dose modification necessary treatment due adverse event , subject must receive least 80 % PEGIFN dose 80 % RBV dose eligible study . HCV genotype 1 ; HCV genotypes exclude . Adults , 18+ year old Written inform consent Liver biopsy within 5 year first dose study drug , document change consistent hepatitis C Adequate bone marrow , liver , renal function demonstrate : Hemoglobin &gt; 12 g/dL female &gt; 13 g/dL male White blood cell ( WBC ) &gt; 3,000/mm3 Neutrophils &gt; 1,500/mm3 Platelets &gt; 80,000/mm3 Total bilirubin &lt; 1.6 mg/dL Direct bilirubin &lt; 1.5 upper limit normal . If indirect bilirubin elevate , Gilbert 's disease must document chart substantiate . Albumin &gt; 3.7 g/dL &lt; 4.9 g/dL Serum creatinine &lt; upper limit normal per central laboratory . If serum creatinine &gt; upper limit normal calculated creatinine clearance &gt; 100 mL/min ( CockcroftGault formula ) patient eligible . Negative pregnancy test woman childbearing potential . Females childbearing potential male partner childbearing potential must use two form effective contraception treatment 6 month treatment conclude . Serum thyroid stimulate hormone ( TSH ) level within normal range within 21 day first study treatment , regardless treatment Lthyroxin . Treatment IFN base therapy and/or antiviral therapy within 30 day first dose study drug Subjects previously receive HCV vaccine ChildPugh Class B C History psychiatric condition include , limited , psychosis , suicidal ideation , major depression . Subjects mild moderate depression past normal mild Beck Depression Inventory score prior history suicidal gesture attempt may enrol , Investigator 's opinion , suitable treatment . Significant cardiovascular disease ( e.g. , New York Heart Association [ NYHA ] class 3 congestive heart failure ; myocardial infarction within past 6 month ; unstable angina ; coronary angioplasty within past 6 month ; uncontrolled atrial ventricular cardiac arrhythmia ) History immunodeficiency autoimmune disease include autoimmune hepatitis , allogeneic transplant , preexist autoimmune antibodymediated disease include , limited : systemic lupus erythematosus , rheumatoid arthritis , multiple sclerosis , Sjogren 's syndrome , autoimmune thrombocytopenia . Other serious medical condition include , limited : HIV1 Hepatitis B ( positive hepatitis B surface antigen [ HBsAg ] ) Cancer ( active tumor last 5 year ) Pregnant , partner pregnant woman , nurse woman Alcohol drug misuse within 90 day screen Use immunosuppressive dos steroid antimetabolite therapy within 3 month entry study ( inhaled topical corticosteroid permit ) . Receipt vaccine immunoglobulin within 30 day first dose study drug . Flu vaccine allow subject qualify 36 additional week treatment . Prior administration oligodeoxynucleotides ( include study medication CPG 10101 ) , ribozymes , know allergy CPG 10101 , interferon , RVN excipients . Receipt investigational drug therapy within 30 day first dose study drug . Any condition , opinion Investigator , may compromise safety compliance subject would preclude subject successful completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis c virus</keyword>
	<keyword>Virus disease</keyword>
	<keyword>Interferon-alpha</keyword>
	<keyword>Interferons</keyword>
	<keyword>Liver disease</keyword>
</DOC>